No Data
No Data
Catalyst Pharmaceuticals Announces Settlement Of FIRDAPSE Patent Litigation With Teva Pharmaceuticals; Teva Will Not Market Its Generic Version Of FIRDAPSE In The U.S. Any Earlier Than February 25, 2035, If Approved By The FDA
Catalyst Pharmaceuticals Price Target Maintained With a $30.00/Share by B of A Securities
Catalyst Pharmaceuticals Analyst Ratings
CPRX Stock Rises 17% on Settling Firdapse Patent Litigation With Teva
Oppenheimer Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $29
Citi Maintains Catalyst Pharmaceuticals(CPRX.US) With Buy Rating, Maintains Target Price $31
Unlock the Full List
Mangkawat : red day but its still stable
Jaguar8 OP Mangkawat : Nothing big news for me on this one unless it comes with a monetary award
Mangkawat Jaguar8 OP : how about $BioLine Rx (BLRX.US)$ bioline rx. any news ? drop and drop.
Jaguar8 OP Mangkawat : It made an offering days ago
Mangkawat Jaguar8 OP : but price look like on risk to be delist. still below $1 .
View more comments...